Literature DB >> 23487373

Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort.

Maxwell A Witt1, Larry Arias, Paul H Katz, Elizabeth T Truong, David J Witt.   

Abstract

BACKGROUND: Unexpected waning of immunity after pertussis vaccination is now well described. In this study we examined whether prior vaccination with whole-cell pertussis vaccine (wP) at any point provided superior protection contrasted with a solely acellular pertussis vaccine (aP) series. We utilized the coincidence of a large outbreak of pertussis with the termination of wP availability, providing populations of children who had been vaccinated with combinations of wP and aP.
METHODS: Kaiser Permanente (KP) is an integrated healthcare system with complete electronic records and a centralized laboratory. Cases of laboratory-confirmed pertussis and vaccination data for members aged 8-20 years were retrieved.
RESULTS: Among 263 496 persons aged 8-20 years, 904 cases of pertussis were identified. In patients with a full history of vaccinations administered by KP, those with 5 total doses of only aP had an 8.57 relative risk (RR) of pertussis (P < .0001) contrasted to those with ≥1 wP dose. With 6 doses of aP, the RR of disease was 3.55 (P < .0001). When external vaccine records were included, the results were similar.
CONCLUSIONS: We found a markedly increased risk of disease associated with an entirely aP series. This risk was mitigated, but not eliminated, by the presence of a sixth dose of pertussis vaccine (Tdap). Receipt of 1 or more wP doses markedly augmented the durability of immunity from subsequent aP doses. It appears that a wholly acellular pertussis vaccine series is significantly less effective and durable than one that contains the traditional whole cell vaccine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23487373     DOI: 10.1093/cid/cit046

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  54 in total

Review 1.  Waning and aging of cellular immunity to Bordetella pertussis.

Authors:  Inonge van Twillert; Wanda G H Han; Cécile A C M van Els
Journal:  Pathog Dis       Date:  2015-09-13       Impact factor: 3.166

Review 2.  Strategies and new developments to control pertussis, an actual health problem.

Authors:  María Emilia Gaillard; Daniela Bottero; Griselda Moreno; Martin Rumbo; Daniela Hozbor
Journal:  Pathog Dis       Date:  2015-08-09       Impact factor: 3.166

3.  The role of B. pertussis vaccine antigen gene variants in pertussis resurgence and possible consequences for vaccine development.

Authors:  Andrew Preston
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

4.  A comparative clinical study to assess safety and reactogenicity of a DTwP-HepB+Hib vaccine.

Authors:  Shashank Dalvi; Prasad S Kulkarni; M A Phadke; S S More; Sanjay K Lalwani; Dipty Jain; Mamta Manglani; B S Garg; Mohan K Doibale; C T Deshmukh
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 5.  Protective Effect of Contemporary Pertussis Vaccines: A Systematic Review and Meta-analysis.

Authors:  T Roice Fulton; Varun K Phadke; Walter A Orenstein; Alan R Hinman; Wayne D Johnson; Saad B Omer
Journal:  Clin Infect Dis       Date:  2016-02-07       Impact factor: 9.079

6.  Characterization of co-purified acellular pertussis vaccines.

Authors:  Yinghua Xu; Yajun Tan; Catpagavalli Asokanathan; Shumin Zhang; Dorothy Xing; Junzhi Wang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Seroepidemiology of diphtheria and pertussis in Beijing, China: A cross-sectional study.

Authors:  Xiaomei Li; Meng Chen; Tiegang Zhang; Juan Li; Yang Zeng; Li Lu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Relationship of immunogenicity to protective potency in acellular pertussis vaccines.

Authors:  Dorothy Xing; Catpagavalli Asokanathan; Ying Hua Xu; Barbara Bolgiano; Alex Douglas-Bardsley; Shumin Zhang; Junzhi Wang; Michael Corbel
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 9.  No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines.

Authors:  Thomas C Mitchell; Carolyn R Casella
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

10.  Bordetella adenylate cyclase toxin is a unique ligand of the integrin complement receptor 3.

Authors:  Radim Osicka; Adriana Osickova; Shakir Hasan; Ladislav Bumba; Jiri Cerny; Peter Sebo
Journal:  Elife       Date:  2015-12-09       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.